President Donald Trump’s directive to impose 100% tariffs on specific patented pharmaceutical products and ingredients will come into effect on Tuesday. However, experts are sceptical about the degree to which this initiative will succeed in stimulating increased drug manufacturing within the United States. That’s because the burden will predominantly impact small and midsize companies that typically lack the resources to adjust or increase production domestically. Experts suggest that the tariffs may compel these pharmaceutical companies to either shut down or consolidate with larger competitors. This scenario could subsequently diminish the variety of medications available to patients and potentially result in increased prices, contrary to Trump’s stated intentions. Moreover, some experts contend that the tariffs may hinder the discovery of new medicines, as these smaller firms are typically more innovative.
The tariffs were announced in April; however, the president had previously indicated a focus on the industry, which had largely avoided such levies for decades owing to a longstanding international agreement aimed at ensuring the unobstructed flow of essential medicines across borders. However, numerous provisions and exceptions will constrain the impact of the tariffs. It is important to note that the levies will not be applicable to the larger pharmaceutical companies that have entered into “Most Favoured Nation” agreements. These manufacturers have committed to enhancing their domestic production and offering their medicines at reduced prices to Medicaid and TrumpRx, the administration’s direct-to-consumer clearinghouse. The vast majority of brand-name drugs are produced by them. Additionally, generic medications, orphan drugs for rare diseases, and specific speciality medicines are predominantly exempt. Patented pharmaceutical products originating from the European Union, Switzerland, Japan, and South Korea, which currently benefit from bilateral trade agreements, will incur a tariff rate of 15%. In contrast, products from the United Kingdom will remain exempt from these levies.
Companies that have an agreement to increase production in the US will encounter a 20% tariff. Industry analysts noted that a small share of pharmaceutical manufacturers and their products will be subject to the 100% tariff rate, following the announcement of the levies. According to a preliminary analysis from the Brookings Institution, over 100 pharmaceutical manufacturers produce at least one non-exempt medication. A majority of these companies lack production facilities; rather, they rely on contract manufacturers for the production of their medications, stated Marta Wosinska. There exists an exceptionally high degree of competition for contract manufacturing capacity in the United States, resulting in significant costs for pharmaceutical companies seeking to increase domestic production of their products, she informed. “Their pockets are not as deep,” she said of the smaller companies. Wosinska noted that many may find themselves compelled to align with larger industry players if they are unable to secure favourable agreements with the White House.
Patients with conditions that remain unaddressed by major pharmaceutical manufacturers may experience the most significant repercussions, as they frequently rely on medications produced by smaller firms. The prices of these medicines will likely rise, stated Mollie Sitkowski. Additionally, she anticipates a decline in the number of new pharmaceuticals introduced in the forthcoming years. The Biotechnology Innovation Organization, representing smaller and mid-sized drugmakers, communicated with the Commerce Department earlier this month, cautioning that “tariffs that punish U.S. innovators are counterproductive and risk slowing the investment and innovation needed to be successful.” And “The reality is that tariffs on America’s medicines will raise costs, impede domestic manufacturing, and divert scarce resources away from research and development critical to maintaining American biotech leadership,” wrote John Crowley.
